Latest news with #Leerink Partners
Yahoo
22-07-2025
- Business
- Yahoo
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an 'Outperform' rating and a $5 price target. The research firm remains confident about the company's long-term prospects following its pivot from an antibody discovery platform to one that develops its internal pipeline. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Leerink Partners is especially bullish about the company's upcoming programs ABCL575, an OX40L antagonist targeting atopic dermatitis, and ABCL635, an NK3R antagonist for vasomotor symptoms. The two programs are scheduled to enter Phase 1 clinical trials in the third quarter of 2025. The research firm also pointed out that AbCellera's existing antibody discovery collaborations are well-positioned to deliver long-term value. It expects the company to benefit from milestone payments and royalties as it leverages antibody capabilities towards a pipeline focused on validated targets. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that focuses on discovering and developing antibody-based medicines. It leverages a proprietary, AI-powered technology platform to search, decode, and analyze natural immune systems, identifying antibodies that can be developed into potential drugs. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
11-07-2025
- Business
- Reuters
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
July 11 (Reuters) - The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's (RARE.O), opens new tab experimental gene therapy to treat a rare inherited disorder, citing manufacturing concerns, the company said on Friday. Shares of the California-based biopharma company fell 5.4% in extended trading. The FDA in its "complete response letter" sought additional information related to the company's production processes and facilities. The regulator's decision comes more than a month ahead of the previously announced action date of August 18. The agency's observations, related to facilities and processes, are addressable and not directly related to the therapy's quality, Ultragenyx said, adding that many of the issues have already been addressed. "It looks like this is a speed bump to approval, rather than a roadblock," Leerink Partners analyst Joseph Schwartz said in a client note. The therapy, UX111, was developed to treat a common type of Sanfilippo syndrome — a group of genetic conditions that begin in early childhood causing severe brain damage and early death. The treatment involves managing symptoms as there are currently no approved disease-modifying medicines. Ultragenyx said the FDA did not cite any review issues related to the clinical data submitted as part of the marketing application. The company's application for UX111 was based on trial data that showed the gene therapy significantly reduced toxic buildup in the brain and improved cognitive and communication skills in children with Sanfilippo syndrome type A. It plans to resubmit updated clinical data from current patients after resolving the FDA's concerns. A new review could take up to six months once the revised application is filed. Ultragenyx acquired the global rights of the therapy from Abeona Therapeutics (ABEO.O), opens new tab through an exclusive license agreement on 2022.
